Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration
A Prospective Masked Pilot Study Comparing Group 1 Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Group 2 Monotherapy - Intravitreal Ranibizumab Alone.
  • Phase

    Phase 2
  • Study Type

  • Status

    Completed No Results Posted
  • Study Participants

The purpose of this study is to compare triple therapy using Photodynamic therapy, intravitreal Dexamethasone and intravitreal Ranibizumab injections versus monotherapy with intravitreal Ranibizumab alone for the treatment of Age-Related Macular Degeneration.
This is a twelve month Phase II prospective masked study comparing Group 1 triple therapy: Same day combination therapy with PDT, 500 microgram dose (0.05cc) intravitreal dexamethasone injection (10mg/ml vial), and a single 0.5 mg intravitreal Ranibizumab injection. This will be compared to Group 2 monotherapy: one intravitreal injection of 0.5 mg Lucentis given every four weeks on a set dosing schedule. Sixty consecutive patients will be enrolled into this clinical trial utilizing the current standard of care guidelines as used at Bay Area Retina Associates. Angiography, fundus photography will be performed at the initial visit and quarterly follow-up visits. Only OCT testing will be performed at all other follow-up visits. Both groups will be re-evaluated for safety at 12 and 24 months.

Group 1 Following the initial treatment, all future re-treatments with Lucentis will be determined on a PRN basis. The decision will be based on clinical examination and imaging evidence of lesion activity. Any evidence of subretinal fluid or cystoid edema on OCT or clinical examination, or evidence of leakage on angiogram will result in re-treatment. If after three consecutive Ranibizumab injections in Group 1, there is any evidence of lesion recurrence or growth of the neovascular membrane associated with visual decline or persistent subretinal fluid, the patient will be treated with repeat PDT/IVD/Lucentis The decision to retreat Group 1 with ranibizumab at each monthly follow-up visit will be dependent on clinical exam, OCT measurements or angiographic findings as documented below.

Group 2 Subjects will receive one intravitreal injection of 0.5 mg Lucentis every four weeks until week 48 or as indicated on the FDA approval label.
Study Started
Aug 31
Primary Completion
Dec 31
Study Completion
Dec 31
Last Update
May 27

Drug ranibizumab, dexamethasone and verteporfin

One 500 microgram dose (0.05cc) intravitreal dexamethasone (10 mg/ml vial) in combination with Visudyne Photodynamic Therapy and 0.5 mg intravitreal Ranibizumab injection on the same day.

Drug Ranibizumab

One 0.5 mg intravitreal Ranibizumab injection

Group 1 Other

Combination triple therapy of Lucentis, Dexamethasone and Visudyne Therapy

Group 2 Other

Monotherapy: One 0.5 mg intravitreal Ranibizumab injection


Inclusion Criteria:

Best Corrected Visual Acuity using ETDRS Charts between 20/32 and 20/400 (Snellen Equivalent) in the study eye with evidence of neovascular ARMD.

(Only one eye will be eligible for study. If both eyes are eligible, the one with the better visual acuity will be selected for treatment unless, based on medical reasons, the investigator deems the other eye to be more appropriate for treatment and study.)

All lesion subtypes will be enrolled with the following criteria

Predominantly classic:
Classic lesion greater than 50% of the total lesion area

Lesion must be less than 12 disc areas

Minimally classic or occult:
CNVM must be greater than or equal to 50% of the total lesion size.
There must be some evidence of recent disease progression (heme, vision loss, recent lesion growth on FA)

Lesion size must be less than 12 disc areas.

Lesions must show recent activity progression with respect to vision, subretinal hemorrhage or subretinal fluid
Less than 12 disc areas in total size
Signed informed consent
Age greater than or equal to 50 years

Exclusion Criteria:

Pigment epithelial detachment greater than 50% of the total lesion size
Previous treatment for ARMD in the study eye
Previous intravitreal drug delivery in the study eye
History of vitrectomy in the study eye
Fibrosis or atrophy involving the center of the fovea in the study eye
Neovascular membrane from any other concurrent retinal disease such as high myopia (SER > -8D), histoplasmosis or other ocular inflammatory disease.
Known history of glaucoma and on more than one topical medication
History of glaucoma filtering surgery in the study eye
History of corneal transplant in the study eye
Patients with co-existing macular disease such as diabetic macular edema
Active intraocular inflammation in the study eye
History of allergy to fluorescein not amenable to treatment
Inability to comply with study or follow up procedures
No Results Posted